Literature DB >> 12672205

Are subjects satisfied with the informed consent process? A survey of research participants.

Janet E Pope1, David P Tingey, J Malcolm O Arnold, Paul Hong, Janine M Ouimet, Adriana Krizova.   

Abstract

OBJECTIVE: Letters of information (LOI) for clinical trials are becoming longer and more complicated. We investigated patients' perspectives of their ability to understand the information presented during a clinical trial. Satisfaction with and motivation for participation in clinical trials were also ascertained. Perceptions from various treatment disciplines were compared.
METHODS: Participants were chosen from 14 clinical trials (departments of rheumatology, ophthalmology, and cardiology) conducted at the same university. Subjects were asked to complete a written questionnaire that assessed demographic information, recall and understanding of information, subjects' decisions to participate, and perceptions/opinions of the study. The response rate was 75% (rheumatology, n = 74; ophthalmology, n = 32; cardiology, n = 84).
RESULTS: The majority of respondents (98%) indicated that they were satisfied with the informed consent process and with their involvement in a trial (97%). Subjects who reported having understood the LOI had better recall of placebo/active drug comparator (p < 0.03), and better understanding of why placebo was used (p < 0.04). No differences were found between those who reported understanding and those who did not on understanding the concept of concealed allocation (blinding). Subjects who felt they had received "the right amount of information" were more likely not to understand concealed allocation. The most frequent reason for trial participation was to help medical science (80%). Subjects with higher education were more likely to understand the reason for placebo use (p < 0.0003), but were not more likely to understand concealed allocation (p < 0.08).
CONCLUSION: Subjects reported that they were satisfied with the informed consent process and their experience in a clinical trial, and that they understood trial concepts. Subjects may be able to self-assess their own level of understanding for trial concepts that intrinsically make sense within the context of their beliefs about medical care, but other trial concepts may be misunderstood/misinterpreted regardless of self-assessment of understanding or education level (i.e., concealed allocation). Subjects may prefer to believe that investigators know which treatment they are receiving, and have made a good treatment decision specific to their case, despite having being told about concealed allocation and placebo use.

Entities:  

Keywords:  Biomedical and Behavioral Research; Empirical Approach

Mesh:

Year:  2003        PMID: 12672205

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  13 in total

1.  Scientific tools, fake treatments, or triggers for psychological healing: how clinical trial participants conceptualise placebos.

Authors:  Felicity L Bishop; Eric E Jacobson; Jessica R Shaw; Ted J Kaptchuk
Journal:  Soc Sci Med       Date:  2012-01-18       Impact factor: 4.634

2.  [Motivation of patients to participate in clinical trials. An explorative survey].

Authors:  Charly Gaul; Annett Malcherczyk; Thomas Schmidt; Jürgen Helm; Johannes Haerting
Journal:  Med Klin (Munich)       Date:  2010-02-20

Review 3.  The quality of informed consent: mapping the landscape. A review of empirical data from developing and developed countries.

Authors:  Amulya Mandava; Christine Pace; Benjamin Campbell; Ezekiel Emanuel; Christine Grady
Journal:  J Med Ethics       Date:  2012-02-07       Impact factor: 2.903

4.  Understanding of placebo controls among older people with schizophrenia.

Authors:  Laura B Dunn; Barton W Palmer; Monique Keehan
Journal:  Schizophr Bull       Date:  2005-09-21       Impact factor: 9.306

5.  Discussing randomised clinical trials of cancer therapy: evaluation of a Cancer Research UK training programme.

Authors:  V Jenkins; L Fallowfield; I Solis-Trapala; C Langridge; V Farewell
Journal:  BMJ       Date:  2005-02-10

Review 6.  Understanding the Concept of Pre-Clinical Autoimmunity: Prediction and Prevention of Systemic Lupus Erythematosus: Identifying Risk Factors and Developing Strategies Against Disease Development.

Authors:  May Y Choi; Karen H Costenbader
Journal:  Front Immunol       Date:  2022-06-03       Impact factor: 8.786

7.  Informed consent and placebo effects: a content analysis of information leaflets to identify what clinical trial participants are told about placebos.

Authors:  Felicity L Bishop; Alison E M Adams; Ted J Kaptchuk; George T Lewith
Journal:  PLoS One       Date:  2012-06-27       Impact factor: 3.240

Review 8.  Participants' understanding of informed consent in clinical trials over three decades: systematic review and meta-analysis.

Authors:  Nguyen Thanh Tam; Nguyen Tien Huy; Le Thi Bich Thoa; Nguyen Phuoc Long; Nguyen Thi Huyen Trang; Kenji Hirayama; Juntra Karbwang
Journal:  Bull World Health Organ       Date:  2015-01-22       Impact factor: 9.408

9.  Informing Patients About Placebo Effects: Using Evidence, Theory, and Qualitative Methods to Develop a New Website.

Authors:  Maddy Greville-Harris; Jennifer Bostock; Amy Din; Cynthia A Graham; George Lewith; Christina Liossi; Tim O'Riordan; Peter White; Lucy Yardley; Felicity L Bishop
Journal:  JMIR Res Protoc       Date:  2016-06-10

10.  Altruism, personal benefit, and anxieties: a phenomenological study of healthy volunteers' experiences in a placebo-controlled trial of duloxetine.

Authors:  Isaac N Kwakye; Matthew Garner; David S Baldwin; Susan Bamford; Verity Pinkney; Felicity L Bishop
Journal:  Hum Psychopharmacol       Date:  2016-07       Impact factor: 1.672

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.